The analysis comes during a year in which RSV has been the target of new vaccines and monoclonal antibody therapies.
Analysis shows 3% prevalence of RSV during pregnancy
More from COVID-19More posts in COVID-19 »
.
The analysis comes during a year in which RSV has been the target of new vaccines and monoclonal antibody therapies.